Andreas Port - Concepedia

Author

Andreas Port

Novartis (Switzerland)ORCID

Also Known As

A Port, A. Port, Ada Port, Andreas Port, J. Upward

Publications

530

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Merck (Germany)Focus (Germany)Ono Pharmaceutical (United States)Boehringer Ingelheim (Germany)

About

Andreas Port is an author at Novartis (Switzerland) specializing in medicine, pharmacotherapy, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	94
2	Pharmacology	3	3	94
3	Public Health	1	1	25
4	Reproductive Health	1	1	25
5	Rheumatology	1	1	23

Andreas Port

Publications

500

Citations

H-Index

Page 1

	Year	Citations
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin <sup>*</sup> Ulrike Graefe‐Mody, Christian Friedrich, Andreas Port, Diabetes Obesity and Metabolism	2011	185
Effect of Rifampin on Apparent Clearance of Everolimus John M. Kovarik, Stefan Hartmann, Joaquim Figueiredo, Annals of Pharmacotherapy	2002	78
Oral‐intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects John M. Kovarik, Stefan Hartmann, Michael G. Bartlett, Biopharmaceutics & Drug Disposition	2007	51
Pharmacokinetic Evaluation of Three Different Intramuscular Doses of Nandrolone Decanoate: Analysis of Serum and Urine Samples in Healthy Men Wilma M. Bagchus, Jean Smeets, H.A.M. Verheul, The Journal of Clinical Endocrinology & Metabolism Therapeutic Drug MonitoringUrologyPharmacokinetic EvaluationPharmacological StudyMedicine	2005	46
Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8 Andreas Port, Jamie Shaw, Lena Klopp‐Schulze, Pharmacology Research & Perspectives	2021	44
The DPP‐4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses Arne Ring, Andreas Port, Eva U. Graefe-Mody, British Journal of Clinical Pharmacology	2011	32
Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults Christian Friedrich, Andreas Port, Arne Ring, Clinical Drug Investigation ContraceptionContraceptive UseHormonal ContraceptiveOral ContraceptiveReproductive Health	2011	25
An Overview of the Pharmacokinetics of Cilomilast (Ariflo®), a New, Orally Active Phosphodiesterase 4 Inhibitor, in Healthy Young and Elderly Volunteers Barry D. Zussman, Lisa J. Benincosa, Dawn M. Webber, The Journal of Clinical Pharmacology RheumatologyPharmacological StudyClinical TherapeuticMedicineChronic Kidney Disease	2001	23
Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants Holger Scheible, Martin C. Dyroff, Annick Seithel‐Keuth, Clinical and Translational Science	2021	16

Page 1